Grifols SA (NASDAQ:GRFS) Receives a Downgrade
Analysts at HSBC Securities’s equities division downgraded the rating for shares of Grifols SA (NASDAQ:GRFS) from a Buy to a Hold on 2 December.
From a total of 2 analysts covering Grifols SA (NASDAQ:GRFS) stock, 1 rate it a ”Buy”, 0 a “Sell”, and 2 a ”Hold”. This means that 33% of the ratings are positive. Grifols SA was the topic of 2 analyst reports since August 17, 2015 according to the firm StockzIntelligence Inc. Berenberg downgraded shares on November 20 to “Hold” rating.
The stock decreased 0.43% or $0.15 during the last trading session, striking $34.6. Approximately 22,307 shares of stock traded hands. Grifols SA, Barcelona (NASDAQ:GRFS) has risen 7.69% since April 29, 2015 and is uptrending. It has outperformed by 7.89% the S&P500.
According to Zacks Investment Research, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain.” Get a free copy of the Zacks research report on Grifols SA, Barcelona (GRFS).